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Dysregulation of non-coding RNA H19 has been observed in various tumors. However, it remains
unknown whether H19 is involved in Bcr-Abl-induced leukemia. Here, we demonstrate a critical
requirement for H19 in Bcr-Abl-mediated tumorigenesis. H19 was highly expressed in Bcr-
Abl-transformed cell lines and primary cells derived from patients in a Bcr-Abl kinase-dependent
manner. Silencing H19 expression sensitized leukemic cells to undergo imatinib-induced apoptosis
and inhibited Bcr-Abl-induced tumor growth. Furthermore, H19 was shown to be regulated by
c-Myc in Bcr-Abl-expressing cells. These results reveal an important role H19 plays in Bcr-Abl-med-
iated transformation and provide novel insights into complex mechanisms underlying
Bcr-Abl-induced cancers.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The Philadelphia chromosome results from a reciprocal translo-
cation between the Bcr gene on chromosome 22 and the c-Abl gene
on chromosome 9, generating the chimeric Bcr-Abl oncogene. The
oncogenic protein Bcr-Abl displays constitutive tyrosine kinase
activity and mediates the pathogenesis of chronic myeloid
leukemia (CML) [1]. Despite extensive studies showing that Bcr-
Abl-induced tumorigenesis is associated with the dysregulation
of a variety of protein-coding genes [2–4], and short non-coding
RNAs (sncRNAs) [5–7], the precise mechanisms by which Bcr-Abl
causes leukemogenesis are not completely elucidated, and the
functional relevance of long non-coding RNAs (lncRNAs) in Bcr-
Abl-mediated cellular transformation remains obscure.
Recently, various lncRNAs have been implicated in many
human diseases including cancers, and emerging studies are begin-
ning to unravel the molecular mechanisms underlying lncRNA
function in these pathological processes [8–11]. The H19 gene is
located within the highly conserved imprinted H19/insulin-like
growth factor 2 (IGF2) locus in which these two genes arereciprocally imprinted, leading to differential allelic expression of
H19 from the maternal allele and IGF2 from the paternal allele
[12]. The human H19 gene encodes a 2.3 kb long, spliced, and poly-
adenylated non-coding RNA that plays important roles in embryo-
nal development and growth control [12–15]. Aberrant H19
expression has also been linked to diverse human cancers.
Although H19 was originally described as a tumor suppressor in
some Wilms’ tumors, embryonic rhabdomyosarcoma, and the
Beckwith–Wiedmann cancer predisposing syndrome [16–19],
increasing evidence showed that H19 expression was upregulated
in breast, liver, endometrial, lung, cervical, esophageal, and bladder
tumors and promoted cancer cell proliferation, suggesting an onco-
genic function for H19 [20–28]. A recent study has demonstrated
that the transcription factor c-Myc causes H19 upregulation that
plays a crucial role in cellular transformation [21]. Conversely,
the tumor suppressor gene p53 has been shown to downregulate
H19 expression in several cancers [29,30]. In addition, H19 also
serves as a precursor for miR-675, a miRNA involved in the
regulation of developmental genes, and implicated in human
colorectal cancer by downregulating the tumor suppressor gene
RB [23,31,32]. These observations demonstrate that H19 may play
dual roles in different cancers either as an oncogene or a tumor
suppressor, which may depend on the reciprocal interactions
between a tumor and its microenvironment. Despite the impor-
tance of H19 in various cancers, the involvement of H19 in
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nism by which H19 functions to impact Bcr-Abl-induced tumori-
genesis remains unknown.
In the present study, we demonstrated the functional involve-
ment of H19 in Bcr-Abl-mediated tumorigenesis. Our results reveal
that the expression of H19 is Bcr-Abl kinase dependent in Bcr-Abl-
positive cell line and primary CML cells derived from patients, and
H19 is required for efﬁcient tumor growth induced by Bcr-Abl.
These ﬁndings reveal an important role for H19 in Bcr-
Abl-mediated leukemogenesis.
2. Materials and methods
2.1. Ethic statement
The mouse experimental design and protocols used in this
study were approved by ‘‘the regulation of the Institute of
Microbiology, Chinese Academy of Sciences of Research EthicsFig. 1. H19 is expressed in K562 leukemic cells in a Bcr-Abl kinase-dependent manner. (
cells infected with the lentivirus encoding Bcr-Abl shRNA (sh-Bcr-Abl) for indicated tim
Bcr-Abl levels in K562 cells treated in a time course with imatinib (10 lM) were detected
are presented as mean ± S.E.M. (n = 3), ⁄P < 0.05. (E and F) RT-PCR, quantitative real-time
treated with indicated concentrations of imatinib for 24 h. Results in (F) are presented aCommittee’’ (Permit No.: PZIMCAS2012001). All mouse experi-
mental procedures were performed in accordance with the Regula-
tions for the Administration of Affairs Concerning Experimental
Animals approved by the State Council of China. For the use of clin-
ical materials for research purposes, prior patients’ consent and ap-
proval were obtained from the Center of Oncology and
Hematology, the First Afﬁliated Hospital of Guangzhou Medical
University, China.
2.2. Cell lines and cell culture
Cell lines K562 and Jurkat were purchased from American Type
Culture Collection (Manassas, VA). Cells were grown in RPMI1640
or Dulbecco’s modiﬁed Eagle medium (DMEM) supplemented with
10% fetal bovine serum and antibiotics (penicillin and streptomy-
cin) as previously described [3]. Bcr-Abl, H19, or c-Myc knockdown
K562 cells were generated by infection of the cells with lentivirus-
es expressing speciﬁc shRNAs in pSIH-H1-GFP vector as describedA and B) RT-PCR and quantitative real-time PCR analysis of H19 expression in K562
e. Results in (B) are presented as mean ± S.E.M. (n = 3), ⁄P < 0.05. (C and D) H19 and
by RT-PCR, quantitative real-time PCR, and Western blotting analysis. Results in (D)
PCR, and Western blotting analysis of expression of H19 and Bcr-Abl in K562 cells
s mean ± S.E.M. (n = 3), ⁄P < 0.05.
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GCAGAGTTCAAAAGCCCTT-30.
2.3. Antibodies and reagents
The following antibodies were used in this study: FLAG (Sigma
F1804 M2), c-Myc (Santa Cruz sc-40 9E10), Bcr (Santa Cruz sc-
885N-20), Bcl-xL (Cell Signaling 2764 54H6), STAT5 (Cell Signaling
9358 3H7), phospho-STAT5 (Tyr694) (Cell Signaling 9359 C11C5).Fig. 2. H19 plays a critical role in regulating survival of K562 leukemic cells. (A) RT-
PCR analysis of H19 expression in primary CML cells from patients, and human
peripheral blood mononuclear cells (normal) after exposure to imatinib (10 lM) for
24 h. (B and C) RT-PCR and quantitative real-time PCR were performed to examine
the expression of H19 in stable K562 cells expressing luciferase or H19 shRNA.
Results in (C) are presented as mean ± S.E.M. (n = 3), ⁄P < 0.05. (D) Survival of K562
cells stably expressing H19-speciﬁc shRNA, or luciferase control was analyzed by
ﬂow cytometry after treatment with imatinib. Results are presented as mean ± -
S.E.M. (n = 3), ⁄P < 0.05. (E) RT-PCR analysis of H19 expression in stable Jurkat cells
expressing luciferase control or H19 shRNA. (F) Survival of Jurkat cells expressing
control or H19 shRNA was analyzed after treatment with or without etoposide.
Results are presented as mean ± S.E.M. (n = 3). (G) Western blotting was performed
to examine the protein levels using indicated antibodies.All other antibodies were obtained and used as described previ-
ously [34].
2.4. RT-PCR, quantitative real-time PCR, and Western blotting
Total RNA was isolated using Trizol reagent (Invitrogen, Carls-
bad, CA). First-strand cDNA was generated using M-MLV Reverse
Transcriptase (Promega, Madison, WI) and oligo (dT) primers
(Takara, Dalian, P.R. China). PCR and quantitative real-time PCR
were performed using rTaq DNA polymerase and SYBR Premix
Ex Taq™ II (Takara, Dalian, P.R. China) respectively. Expression le-
vel of actin was used as a reference control. Where indicated, RT-
PCR signals were quantiﬁed by densitometry. Quantitative real-
time PCR was performed using the Applied Biosystems 7300 real-
time PCR System (Applied Biosystems, Foster City, USA).
Western blotting was conducted as previously described [35].
Brieﬂy, cells were treated as indicated in ﬁgure legends and then
lysed for protein collection. Samples were separated on SDS–poly-
acrylamide gel, transferred to a nitrocellulose membrane, and
probed with indicated antibodies. Where indicated, Western blot
signals were quantiﬁed by densitometry.
2.5. Flow cytometry and apoptosis assay
Cells were washed extensively in medium and cultured with
imatinib (10 lM) for the indicated time, then stained with propidi-
um iodode (PI)/Annexin V, and analyzed by ﬂuorescence-activated
cell sorter (BD Bioscience, San Jose, CA).
2.6. Xenograft model in nude mice
Nude-mouse injection was performed as previously described
[3]. Brieﬂy, cells were washed extensively in phosphate buffered
saline (PBS) and then injected subcutaneously into female nude
mouse (5–6 weeks old). Tumor growth was monitored and mea-
sured in volume (length  height width) at the indicated time
after inoculation. Bioluminescent imaging was used to probe tu-
mor growth from GFP-positive cells. Images were quantiﬁed as
photons/s using Indigo software (Berthold Technologies, Bad Wild-
bad, Germany).
2.7. Statistical analysis
Results were reported as mean values ± standard error
(mean ± S.E.). Statistical signiﬁcance was determined by Student’s
t-test analysis. A level of P < 0.05 was considered to be signiﬁcant.
3. Results
3.1. H19 is expressed in Bcr-Abl-positive leukemic cells in a Bcr-Abl
kinase-dependent manner
To identify lncRNAs involved in Bcr-Abl-mediated cellular trans-
formation, we performed previously an analysis of lncRNA expres-
sion in response to Bcr-Abl levels using lncRNA cDNA microarray
(NCBI Gene Expression Omnibus database access number
GSE42269). Interestingly, we found that the expression of lncRNA
H19 was signiﬁcantly downregulated upon disruption of Bcr-Abl
expression in human K562 leukemic cells. To validate this ﬁnding,
RT-PCR and quantitative real-time PCR were performed to examine
H19 expression in Bcr-Abl knockdown K562 cells. Indeed, we
observed that silencing Bcr-Abl expression signiﬁcantly decreased
the level of H19 in K562 cells (Fig. 1A and B). Strikingly, similar
expression pattern of H19 was seen in the case of imatinib
treatment, a speciﬁc Abl tyrosine kinase inhibitor. As shown in
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K562 cells with imatinib in a dose dependent or in a time course
dependent manner, while treatment with etoposide had no
signiﬁcant effect on H19 expression in the cells (Supplementary
Fig. S1A). Additionally, our results showed that imatinib treatment
could not reduce the level of H19 in Bcr-Abl-negative cell lines (Sup-
plementary Fig. S1B). Together, these results suggest that expres-
sion of H19 is Bcr-Abl kinase dependent in Bcr-Abl-transformed
cells.
3.2. H19 plays a critical role in regulating survival of Bcr-Abl-positive
leukemic cells
Because our results revealed that H19 expression was tightly
regulated by Bcr-Abl kinase, we reasoned that H19 may play an
important role in Bcr-Abl-mediated oncogenic transformation. To
test this possibility, we determined whether H19 is expressed in
Bcr-Abl-positive leukemic cells derived from CML patients. Indeed,
we observed that H19 was highly expressed in Bcr-Abl-expressingFig. 3. H19 deﬁciency attenuates tumor formation induced by K562 leukemic cells in xe
expressing shRNA targeting H19 (sh-H19) or luciferase control (sh-luc). The tumor v
independent experiments. Error bars represent S.E. n = 9. ⁄P < 0.05. (B) Tumors were excis
with similar results. (C) Relative volume of tumors excised from nude mice injected wit
control cells is 1. Error bars represent S.E. n = 9. ⁄P < 0.05. (D) Over a 28-day period after i
by bioluminescent imaging. Shown are representative images from at least three indepe
tumors formed by K562 cells expressing control or H19 shRNA was examined by RT-PCR
(n = 3), ⁄P < 0.05.primary CML cells derived from 4 patients, and imatinib treatment
greatly decreased the expression of H19 in these cells but not in
normal control cells (Fig. 2A). Then we generated K562 cells stably
expressing speciﬁc shRNAs targeting either H19 or luciferase
control (Supplementary Fig. S2A). The interference efﬁciency of
these shRNAs in cells was determined (Fig. 2B and C). Subse-
quently, the effect of silencing H19 expression on survival of
K562 cells was investigated. The cells underwent apoptosis follow-
ing imatinib treatment, and approximately 56% of control cells
remained viable after incubation with this inhibitor for 40 h under
our culture condition. In contrast, only approximately 38% of H19
knockdown cells were viable under the same conditions
(Fig. 2D). We observed that there was only a slight decrease in
the proliferation of cells expressing H19 shRNA in the absence of
imatinib (Supplementary Fig. S2B). In addition, we found that over-
expression of Bcr-Abl resulted in an increased survival of H19
knockdown K562 cells (Supplementary Fig. S2C). Interestingly,
although H19 was expressed in Jurkat cell (a Bcr-Abl-negative
leukemic cell line), depletion of H19 expression had no signiﬁcantnograft mouse model. (A) Nude mice were subcutaneously injected with K562 cells
olumes were measured at indicated time points. Plotted are results from three
ed from mice. Shown are representative images from four independent experiments
h H19 knockdown or control K562 cells. The average volume of tumors induced by
noculation, tumors caused by H19 knockdown or control K562 cells were measured
ndent experiments with similar results. (E and F) H19 expression in representative
(E) and quantitative real-time PCR (F). Results in (F) are presented as mean ± S.E.M.
Fig. 4. C-Myc-dependent expression of H19 in K562 leukemic cells. (A and B) RT-PCR analysis of expression of c-Myc and H19 in K562 cells treated with Bcr-Abl shRNA (sh-
Bcr-Abl) (A), or imatinib (B). (C) The levels of c-Myc and H19 in c-Myc knockdown (sh-c-Myc) or control K562 cells were examined by RT-PCR and Western blotting. (D) RT-
PCR was performed to examine H19 levels in K562 cells expressing luciferase control or STAT5 shRNA. (E) RT-PCR and Western blotting analysis of expression of c-Myc and
H19 in control or c-Myc overexpressing (c-Myc) K562 cells treated with or without imatinib.
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plementary Figs. S2D and S2E). These data suggest that H19 is in-
volved in regulating survival of Bcr-Abl-positive leukemic cells.
Previous studies have demonstrated that altered apoptosis
proﬁles in Bcr-Abl-transformed cells are associated with several
anti-apoptotic proteins, including STAT5-dependent expression of
Bcl-xL [36]. To provide insights into the mechanism by which
H19 regulates survival of Bcr-Abl-expressing cells, we evaluated
the activation of STAT5 and expression of Bcl-xL in the leukemic
cells. Our results showed that depletion of H19 expression
signiﬁcantly inhibited STAT5 phosphorylation and decreased the
level of Bcl-xL protein in the cells (Fig. 2G, Supplementary
Fig. S2F), suggesting that H19 may modulate leukemic cell survival
by regulating STAT5 activity that mediates Bcl-xL expression.
3.3. H19 deﬁciency attenuates tumor formation induced by K562
leukemic cells in xenograft mouse model
To further conﬁrm the functional relevance of H19 in Bcr-Abl-
induced tumorigensis, we investigated the effect of silencing H19
on tumor formation of K562 cells using xenograft model in nude
mice. Nude mice were inoculated subcutaneously with K562 cells
stably expressing shRNAs targeting either H19 or luciferase con-
trol. Notably, we observed that the tumors formed by control cells
grew much faster than those formed by H19 knockdown cells
(Fig. 3A). At least three independent experiments were performed
to ensure the reliability of the results and consistency of data
(Fig. 3B). By statistical analysis, we found that depletion of H19
expression in K562 cells signiﬁcantly inhibited the tumor growth
(Fig. 3C). These observations were further conﬁrmed by biolumi-
nescent imaging analysis (Fig. 3D). In addition, RT-PCR andquantitative real-time PCR analysis of tumor extracts demon-
strated the H19 deﬁciency in the tumor cells expressing H19-spe-
ciﬁc shRNA (Fig. 3E and F). Together, these results suggest that H19
is required for efﬁcient tumor growth induced by Bcr-Abl.
3.4. The expression of H19 is c-Myc-dependent in K562 leukemic cells
Because our data presented above revealed that disruption of
H19 expression has profound effects on Bcr-Abl-mediated tumorig-
ensis, we then asked how high expression of H19 is induced by Bcr-
Abl in the leukemic cells. It has been shown that c-Myc and Bcr-Abl
cooperate to mediate the transformation of hematopoietic cells,
which is critical for Bcr-Abl oncogenicity [37,38]. In addition,
c-Myc could directly induce H19 expression by binding to evolu-
tionarily conserved E-boxes near the imprinting control region to
facilitate histone acetylation and transcriptional initiation of the
H19 promoter [21]. Thus, we determined whether c-Myc was
involved in regulation of the H19 expression in K562 leukemic cells.
As shown in Fig. 4A and B, disruption of Bcr-Abl expression or inac-
tivation of Abl kinase resulted in a decreased expression of c-Myc
with simultaneously reduced levels of H19, showing the similar
regulation pattern of c-Myc and H19 by Bcr-Abl (Supplementary
Figs. S4A and S4B). Importantly, silencing c-Myc expression alone
in K562 cells signiﬁcantly decreased the level of H19, while deple-
tion of STAT5 exerted no signiﬁcant inﬂuence on the expression of
H19 (Fig. 4C and D, Supplementary Figs. S3A, and S4C). In contrast,
forced expression of c-Myc led to increased H19 levels in K562 cells
treated with or without imatinib (Fig. 4E, Supplementary Figs. S3B
and S4D). Taken together, these data provide strong evidence that
expression of H19 is c-Myc-dependent. This may be a mechanism
by which Bcr-Abl regulates H19 levels in the leukemic cells.
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Cellular transformation by Bcr-Abl oncogene is a complicated
process that requires the activation of several proliferative signal-
ing pathways and the disruption of apoptosis. But thus far, little
information is available about how lncRNAs are implicated in the
Bcr-Abl-mediated tumorigenesis. In this study, our experiments
demonstrate that lncRNA H19 is involved in this process. Remark-
ably, H19 was found to be downregulated in the case of Bcr-Abl
silencing, indicating that expression of H19 is Bcr-Abl dependent
in K562 leukemic cells. Furthermore, we revealed that disruption
of H19 expression sensitized leukemic cells to undergo apoptosis
and inhibited Bcr-Abl-induced tumorigenesis in vivo, suggesting
a functional involvement of H19 in Bcr-Abl-mediated cellular
transformation.
The majority of human genome does not code for proteins and
widespread studies have been carried out to interrogate the roles
of ‘‘non-coding’’ genes [39,40]. As a newly emerging class of non-
coding RNAs, lncRNAs are of particular interest. Accumulating evi-
dence has revealed that lncRNAs may function in a wide range of
physiological processes and can regulate multiple levels of the
gene expression by diverse mechanisms [8,41,42]. In addition,
numerous lncRNAs have been demonstrated to hold a key position
in the cancer paradigm [9,43–46]. The developmentally regulated
lncRNA, H19 is abundantly expressed in fetal tissues and downreg-
ulated after birth, except in adult skeletal muscle and heart [12,32].
Recently, emerging studies have shown that the dysregulation of
H19 is associated with diverse human genetic disorders and can-
cers, and the dual roles for H19 acting either as a tumor suppressor
or an oncogene have been suggested [19,21–23]. Despite these
promising ﬁndings, investigations related to H19 function in
hematologic malignancies appear to be fragmentary, and are not
as extensively depicted as those in solid tumors. In this study,
our experiments demonstrate a critical requirement for H19 in
Bcr-Abl-induced tumorigenesis, and provide novel insights into
the complicated mechanisms by which Bcr-Abl causes leukemo-
genesis. This work is the ﬁrst report of the functional relevance
of H19 in Bcr-Abl-mediated cellular transformation. However, the
precise mechanisms by which H19 impacts these processes remain
to be determined.
Our study has also attempted to address the mechanism by
which Bcr-Abl may regulate H19 expression in K562 leukemic
cells. Although it has been suggested that c-Myc, an oncogenic
transcription factor, can upregulate H19 expression in breast and
lung cancers [21], it is unclear whether c-Myc is involved in regu-
lating the H19 expression in leukemic cells. Here, we found that
loss of either Bcr-Abl expression or Abl kinase activity caused
decrease of c-Myc levels with simultaneously reduced levels of
H19. Furthermore, we demonstrated that depletion of c-Myc alone
in K562 cells signiﬁcantly decreased the level of H19, suggesting
that H19 is expressed in a c-Myc-dependent manner in K562
leukemic cells. However, further studies are needed to better
understand the signaling pathways that regulate H19 expression
in Bcr-Abl positive leukemic cells. In addition, it is interesting to
address the biological signiﬁcance of the Bcr-Abl/c-Myc/H19 path-
way in human leukemia patients. These remain an ongoing task.Conﬂict of interest
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